SHS invests in Swiss life science company evitria AG
The SHS V fund managed by Tübingen-based SHS Gesellschaft für Beteiligungsmanagement has acquired a joint stake in Swiss evitria AG together with AFINUM. The life science company supplies large pharmaceutical and biotech companies with customized antibodies for research purposes. For SHS, it is the first investment from its SHS V fund, which had its first closing in July 2018.
Based in Schlieren near Zurich, evitria AG is a customized antibody production service provider. The company looks back on a track record of more than 5,000 produced antibody-based molecules. Evitria’s customers are leading global pharmaceutical companies as well as academic laboratories and biotech companies from North America, Europe, Asia and Australia.
Many of the world’s top-selling drugs are therapeutic antibodies. Accordingly, drug developers are conducting intensive research into other antibody-based drugs for diseases such as cancer or neurological diseases such as dementia. They require specialized and reliable suppliers for this purpose. The market in which evitria operates will therefore continue to grow dynamically in the coming years.
SHS and AFINUM are acquiring a stake in evitria AG, founded in 2010, with the aim of developing new customer groups and establishing a business unit in the USA to serve the local market directly. This is the first joint investment for SHS and AFINUM.
Cornelius Maas, Senior Investment Manager at SHS, says: “We are delighted to be working with AFINUM and the experienced management team to develop this fast-growing company internationally. The antibody production process at evitria is characterized by high levels of efficiency, quality and stability with very short delivery times. In short, evitria combines an established, leading market position with high growth potential. These characteristics serve as guiding principles for all further investments made by our SHS V fund.”
About SHS Gesellschaft für Beteiligungsmanagement mbH
SHS Gesellschaft für Beteiligungsmanagement is based in Tübingen, Germany and invests in medical technology and life science companies with a focus on expansion financing, changes in shareholder structures and successor situations. SHS holds minority as well as majority interests. The company was founded in 1993 and has since gained extensive experience as an industry investor, which supports the growth of its portfolio companies through a network of partnerships regarding the introduction of new products, regulatory issues or entering new markets. The SHS fund’s German and international investors include professional pension insurers, retirement funds, strategic investors, funds of funds, family offices, entrepreneurs and the SHS management team. The AIFM-registered company invests up to €30 million in equity capital and volumes exceeding this amount are implemented with a network of co-investors. Following its first closing with more than €90 million in July 2018, the fifth SHS fund is already being invested. The final will take place in July 2019.
Further information: https://www.shs-capital.eu
Tel.: +49 (0) 89 2000 3035
Fax: +49 (0) 89 2000 3040